留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

非小细胞肺癌免疫检查点抑制剂治疗进展

王硕 邓云天 彭欢 张向峰

王硕, 邓云天, 彭欢, 张向峰. 非小细胞肺癌免疫检查点抑制剂治疗进展[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0151
引用本文: 王硕, 邓云天, 彭欢, 张向峰. 非小细胞肺癌免疫检查点抑制剂治疗进展[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0151
WANG Shuo, DENG Yuntian, PENG Huan, ZHANG Xiangfeng. Progress in the treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0151
Citation: WANG Shuo, DENG Yuntian, PENG Huan, ZHANG Xiangfeng. Progress in the treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0151

非小细胞肺癌免疫检查点抑制剂治疗进展

doi: 10.12290/xhyxzz.2022-0151
详细信息
    通讯作者:

    张向峰,E-mail:xfzh20008@163.com

  • 中图分类号: R734;R453

Progress in the treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors

  • 摘要: 肺癌是全球范围内发病率及死亡率极高的恶性肿瘤,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)最为常见。NSCLC的传统治疗主要依靠化学药物进行,近年来免疫治疗已成为NSCLC治疗热点并取得了令人瞩目的进展,免疫治疗对NSCLC患者的总体客观缓解率约为20%。大量新的生物免疫制剂被开发和应用于临床,其中免疫检查点抑制剂(immune checkpointinhibitors,ICI)对NSCLC开发最广、疗效最为肯定,本文对近年NSCLC免疫治疗生物标志物研究现状和进展进行综述,以期提高免疫治疗精准度,更好地指导NSCLC患者的个体化治疗。
  • [1] Garon EB, Rizvi NA, Hui RN, et al.Pembrolizumab for the Treatment of Non-small-cell Lung Cancer[J].N Engl J Med, 2015, 372:2018-2028.
    [2] Brahmer J, Reckamp KL, Baas P, et al.Nivolumab Versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer[J].N Engl J Med, 2015, 373:123-135.
    [3] Jiang C, Yi L, Gao X, et al.[Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer] [J].Zhongguo Fei Ai Za Zhi, 2022, 25:46-53.
    [4] Reck M, Ciuleanu TE, Cobo M, et al.First-line Nivolumab Plus Ipilimumab With Two Cycles of Chemotherapy Versus Chemotherapy Alone (Four Cycles) in Advanced Non-small-cell Lung Cancer:CheckMate 9LA 2-year Update[J].ESMO Open, 2021, 6:100273.
    [5] Reck M, Rodríguez-Abreu D, Robinson AG, et al.Pembrolizumab Versus Chemotherapy for PD-L1-Positive Non-SmallCell Lung Cancer[J].N Engl J Med, 2016, 375:1823-1833.
    [6] Pardoll DM.The Blockade of Immune Checkpoints in Cancer Immunotherapy[J].Nat Rev Cancer, 2012, 12:252-264.
    [7] Tekguc M, Wing JB, Osaki M, et al.Treg-expressed CTLA-4 Depletes CD80/CD86 by Trogocytosis, Releasing Free PDL1 on Antigen-presenting Cells[J].Proc Natl Acad Sci U S A, 2021, 118:e2023739118.
    [8] Morad G, Helmink BA, Sharma P, et al.Hallmarks of Response, Resistance, and Toxicity to Immune Checkpoint Blockade[J].Cell, 2021, 184:5309-5337.
    [9] Reck M, Rodríguez-Abreu D, Robinson AG, et al.Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50[J].J Clin Oncol, 2021, 39:2339-2349.
    [10] Ma CL, Sun X, Shen D, et al.Ectopic Expression of LAG-3 in non-Small-cell Lung Cancer Cells and Its Clinical Significance[J].J Clin Lab Anal, 2020, 34:e23244.
    [11] Datar I, Sanmamed MF, Wang J, et al.Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human NonSmall Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis[J].Clin Cancer Res, 2019, 25:4663-4673.
    [12] Ding L, Getz G, Wheeler DA, et al.Somatic Mutations Affect Key Pathways in Lung Adenocarcinoma[J].Nature, 2008, 455:1069-1075.
    [13] Levin SD, Taft DW, Brandt CS, et al.Vstm3 Is a Member of the CD28 Family and an Important Modulator of T-cell Function[J].Eur J Immunol, 2011, 41:902-915.
    [14] Stanietsky N, Rovis TL, Glasner A, et al.Mouse TIGIT Inhibits NK-cell Cytotoxicity Upon Interaction With PVR[J].Eur J Immunol, 2013, 43:2138-2150.
    [15] Dardalhon V, Schubart AS, Reddy J, et al.CD226 Is Specifically Expressed on the Surface of Th1 Cells and Regulates Their Expansion and Effector Functions[J].J Immunol, 2005, 175:1558-1565.
    [16] Ocaña-Guzman R.Torre-Bouscoulet L, Sada-Ovalle I.TIM-3 Regulates Distinct Functions in Macrophages[J].Front Immunol, 2016, 7:229.
    [17] Zhou KJ, Guo S, Tong S, et al.Immunosuppression of Human Adipose-Derived Stem Cells on T cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways[J].Stem Cells Dev, 2018, 27:1191-1202.
    [18] He YY, Yu H, Rozeboom L, et al.LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes[J].J Thorac Oncol, 2017, 12:814-823.
    [19] Wennerberg E, Mukherjee S, Spada S, et al.Expression of the mono-ADP-ribosyltransferase ART1 by Tumor Cells Mediates Immune Resistance in Non-small Cell Lung Cancer[J].Sci Transl Med, 2022, 14:eabe8195.
    [20] Wiede F, Lu KH, Du X, et al.PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity[J].Cancer Discov, 2022, 12:752-773.
    [21] Kuske M, Haist M, Jung T, et al.Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?[J].Cancers (Basel), 2022, 14:1710.
    [22] Mao SQ, Zhou F, Liu YW, et al.ICI Plus Chemotherapy Prolonged Survival Over ICI Alone in Patients With Previously Treated Advanced NSCLC[J].Cancer Immunol Immunother, 2022, 71:219-228.
    [23] Ma XT, Zhang YJ, Wang S, et al.Immune Checkpoint Inhibitor (ICI) Combination Therapy Compared to Monotherapy in Advanced Solid Cancer:a Systematic Review[J].J Cancer, 2021, 12:1318-1333.
    [24] Brueckl WM, Ficker JH, Zeitler G.Clinically Relevant Prognostic and Predictive Markers for Immune-checkpointinhibitor (ICI) Therapy in Non-small Cell Lung Cancer (NSCLC)[J].BMC Cancer, 2020, 20:1185.
    [25] Paz-Ares L, Ciuleanu TE, Cobo M, et al.First-line Nivolumab Plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-small-cell Lung Cancer (CheckMate 9LA):an International, Randomised, Openlabel, Phase 3 Trial[J].Lancet Oncol, 2021, 22:198-211.
    [26] Muto S, Inomata S, Yamaguchi H, et al.CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLC[J].Anticancer Res, 2021, 41:6267-6272.
    [27] Wilkins A, McDonald F, Harrington K, et al.Radiotherapy Enhances Responses of Lung Cancer to CTLA-4 Blockade[J].J Immunother Cancer, 2019, 7:64.
    [28] Lynch TJ, Bondarenko I, Luft A, et al.Ipilimumab in Combination With Paclitaxel and Carboplatin as First-line Treatment in Stage IIIB/IV Non-small-cell Lung Cancer:Results From a Randomized, Double-blind, Multicenter Phase II Study[J].J Clin Oncol, 2012, 30:2046-2054.
    [29] Jiang CJ, Zhang L, Xu XP, et al.Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4[J].Adv Sci (Weinh), 2021, 8:e2102500.
    [30] Zhou YX, Lin Z, Zhang XY, et al.First-line Treatment for Patients With Advanced Non-small Cell Lung Carcinoma and High PD-L1 Expression:Pembrolizumab or Pembrolizumab Plus Chemotherapy[J].J Immunother Cancer, 2019, 7:120.
    [31] Nassabein R, Gaudreau PO, Belkaid W, et al.A Phase I/II Study of Pembrolizumab in Combination With Nab-paclitaxel in Patients With Unresectable Stage III or Stage IV non Small-cell Lung Carcinoma (NSCLC)[J].Cancer Treat Res Commun, 2021, 28:100421.
    [32] Incorvaia L, Fanale D, Badalamenti G, et al.Programmed Death Ligand 1(PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)[J].Adv Ther, 2019, 36:2600-2617.
    [33] Leighl NB, Hellmann MD, Hui R, et al.Pembrolizumab in Patients With Advanced Non-small-cell Lung Cancer (KEYNOTE-001):3-year Results From an Open-label, Phase 1 Study[J].Lancet Respir Med, 2019, 7:347-357.
    [34] Mansfield AS, Herbst RS, de Castro G, et al.Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases:Pooled Analysis of KEYNOTE-001, 010, 024, and 042[J].JTO Clin Res Rep, 2021, 2:100205.
    [35] Oki R, Hirakawa Y, Kimura H, et al.Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma[J].Intern Med, 2020, 59:977-981.
    [36] Shionoya Y, Hirohashi Y, Takahashi H, et al.Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab:A Case Report[J].Anticancer Res, 2021, 41:3699-3706.
    [37] Brahmer JR, Govindan R, Anders RA, et al.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)[J].J Immunother Cancer, 2018, 6:75.
    [38] Tobita S, Kinehara Y, Tamura Y, et al.Successful Continuous Nivolumab Therapy for Metastatic Non-small Cell Lung Cancer After Local Treatment of Oligometastatic Lesions[J].Thorac Cancer, 2020, 11:2357-2360.
    [39] Figueiredo A, Almeida MA, Almodovar MT, et al.Real-world Data From the Portuguese Nivolumab Expanded Access Program (EAP) in Previously Treated Non Small Cell Lung Cancer (NSCLC)[J].Pulmonology, 2020, 26:10-17.
    [40] Schmid S, Diem S, Li QY, et al.Organ-specific Response to Nivolumab in Patients With Non-small Cell Lung Cancer (NSCLC)[J].Cancer Immunol Immunother, 2018, 67:1825-1832.
    [41] Hellmann MD, Paz-Ares L, Bernabe Caro R, et al.Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer[J].N Engl J Med, 2019, 381:2020-2031.
    [42] Paz-Ares LG, Ramalingam SS, Ciuleanu TE, et al.First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC:4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial[J].J Thorac Oncol, 2022, 17:289-308.
    [43] Vokes EE, Ready N, Felip E, et al.Nivolumab Versus Docetaxel in Previously Treated Advanced Non-small-cell Lung Cancer (CheckMate 017 and CheckMate 057):3-year Update and Outcomes in Patients With Liver Metastases[J].Ann Oncol, 2018, 29:959-965.
    [44] Naito T, Umemura S, Nakamura H, et al.Successful Treatment With Nivolumab for SMARCA4-deficient Non-small Cell Lung Carcinoma With a High Tumor Mutation Burden:a Case Report[J].Thorac Cancer, 2019, 10:1285-1288.
    [45] Kim JS, Nam TS, Kim J, et al.Myasthenia Gravis and Myopathy After Nivolumab Treatment for Non-small Cell Lung Carcinoma:a Case Report[J].Thorac Cancer, 2019, 10(10):2045-2049.
    [46] Antonia SJ, Villegas A, Daniel D, et al.Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer[J].N Engl J Med, 2017, 377:1919-1929.
    [47] Li DN, Lu WQ, Yang BW, et al.Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients:A Meta-Analysis[J].Front Immunol, 2021, 12:666909.
    [48] Fehrenbacher L, Spira A, Ballinger M, et al.Atezolizumab Versus Docetaxel for Patients With Previously Treated Nonsmall-cell Lung Cancer (POPLAR):a Multicentre, Open-label, Phase 2 Randomised Controlled Trial[J].Lancet, 2016, 387:1837-1846.
    [49] Zhou Q, Chen M, Jiang O, et al.Sugemalimab Versus Placebo After Concurrent or Sequential Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III Non-small-cell Lung Cancer in China (GEMSTONE-301):Interim Results of a Randomised, Double-blind, Multicentre, Phase 3 Trial[J].Lancet Oncol, 2022, 23:209-219.
    [50] Zhou CC, Wang ZP, Sun YP, et al.Sugemalimab Versus Placebo, in Combination With Platinum-based Chemotherapy, as First-line Treatment of Metastatic Non-small-cell Lung Cancer (GEMSTONE-302):Interim and Final Analyses of a Double-blind, Randomised, Phase 3 Clinical Trial[J].Lancet Oncol, 2022, 23:220-233.
    [51] Boyer M, Şendur MAN, Rodríguez-Abreu D, et al.Pembrolizumab Plus Ipilimumab or Placebo for Metastatic NonSmall-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%:Randomized, Double-Blind Phase III KEYNOTE-598 Study[J].J Clin Oncol, 2021, 39:2327-2338.
    [52] Zhou J, Yu X, Hou LK, et al.Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Remodels Tumor Microenvironment by Upregulating LAG-3 in Advanced Non-small-cell Lung Cancer[J].Lung Cancer, 2021, 153:143-149.
    [53] Anon.Tiragolumab Impresses in Multiple Trials[J].Cancer Discov, 2020, 10:1086-1087.
    [54] Houssaini MS, Damou M, Ismaili N.Advances in the Management of Non-small Cell Lung Cancer (NSCLC):A New Practice Changing Data From asco 2020 Annual Meeting[J].Cancer Treat Res Commun, 2020, 25:100239.
    [55] Horvath L, Pircher A.ASCO 2020 Non-small Lung Cancer (NSCLC) Personal Highlights[J].Memo, 2021, 14:66-69.
    [56] Niu J, Maurice-Dror C, Lee DH, et al.First-in-human Phase 1 Study of the anti-TIGIT Antibody Vibostolimab as Monotherapy or With Pembrolizumab for Advanced Solid Tumors, Including Non-small-cell Lung Cancer[J].Ann Oncol, 2022, 33:169-180.
    [57] Anon.An Anti-TIGIT Antibody with a PD-1 Inhibitor Shows Promise in Solid Tumors[J].Cancer Discov, 2022, 12:14.
    [58] Gomes de Morais AL, Cerdá S, de Miguel M.New Checkpoint Inhibitors on the Road:Targeting TIM-3 in Solid Tumors[J].Curr Oncol Rep, 2022, 24:651-658.
    [59] Curigliano G, Gelderblom H, Mach N, et al.Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors[J].Clin Cancer Res, 2021, 27:3620-3629.
    [60] Khunger M, Hernandez AV, Pasupuleti V, et al.Programmed Cell Death 1(PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors:A Systematic Review and MetaAnalysis[J].JCO Precis Oncol, 2017, 1:1-15.
    [61] Yun J, Lee SH, Kim SY, et al.Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC[J].Cancer Discov, 2020, 10:1194-1209.
    [62] Park K, Haura EB, Leighl NB, et al.Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy:Initial Results From the CHRYSALIS Phase I Study[J].J Clin Oncol, 2021, 39:3391-3402.
    [63] Syed YY.Amivantamab:First Approval[J].Drugs, 2021, 81:1349-1353.
  • 加载中
计量
  • 文章访问数:  11
  • HTML全文浏览量:  0
  • PDF下载量:  2
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-03-26
  • 录用日期:  2022-05-27
  • 网络出版日期:  2022-08-10

目录

    /

    返回文章
    返回

    【通知】尊敬的读者、作者及编者:因特殊原因,本站自2022.9.30至10.24日期间实施6—24点开放,其他时段访问受限,给您带来不便敬请谅解!10.25日恢复如常。